Effects on mortality of early vs late administration of convalescent plasma in the treatment of Covid-19
- 1 August 2021
- journal article
- research article
- Published by Elsevier in Transfusion and Apheresis Science
- Vol. 60 (4) , 103148
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent PlasmaJAMA, 2020
- Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in ChinaJAMA, 2020
- Effectiveness of convalescent plasma therapy in severe COVID-19 patientsProceedings of the National Academy of Sciences, 2020
- Drug treatment options for the 2019-new coronavirus (2019-nCoV)BioScience Trends, 2020
- Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitroCell Research, 2020
- Clinical features of patients infected with 2019 novel coronavirus in Wuhan, ChinaThe Lancet, 2020
- The Use of TKM-100802 and Convalescent Plasma in 2 Patients With Ebola Virus Disease in the United StatesClinical Infectious Diseases, 2015
- The Effectiveness of Convalescent Plasma and Hyperimmune Immunoglobulin for the Treatment of Severe Acute Respiratory Infections of Viral Etiology: A Systematic Review and Exploratory Meta-analysisThe Journal of Infectious Diseases, 2014
- Convalescent Plasma Treatment Reduced Mortality in Patients With Severe Pandemic Influenza A (H1N1) 2009 Virus InfectionClinical Infectious Diseases, 2011
- Experience of using convalescent plasma for severe acute respiratory syndrome among healthcare workers in a Taiwan hospitalJournal of Antimicrobial Chemotherapy, 2005